JNJ — Johnson & Johnson

The market is constructive after Q2 2026 sales grew 6.6% to $25.31B, adjusted EPS beat at $2.90, and management lifted FY2026 operational sales growth to 6.5%-7.1% and adjusted EPS to roughly $11.50. Defensive rotation, the 64th consecutive dividend increase, and a Buy-rated analyst consensus add to the positive tone, although the ~$280-282 price target leaves only mid-single-digit upside from current levels.

Revenue has inflected upward over the last three years: quarterly sales went from ~$21.35B in late 2023 to $23.74B in Q2 2025 and $25.31B in Q2 2026, with YoY growth of 9.9% in Q1 2026 and 6.6% in Q2 2026. Clean operating margins have stayed in the high-20s percentage range, but GAAP net income is noisy because of one-time items—Q1 2025 EPS of $4.54 included a large tax-related benefit, while late-2024 quarters carried charges—so adjusted EPS and cash flow are more reliable for the trend. TTM free cash flow through Q2 2026 is roughly $18.7B, up about 14% YoY, but quarterly FCF is lumpy ($1.47B in Q1 2026, $3.39B in Q2 2026).

On trailing GAAP multiples, JNJ looks expensive: P/E is 30.7x versus the 20.4x five-year average, and P/S is 6.54x versus 5.08x. But trailing GAAP EPS is depressed by charges, so the more useful metric is ~22.9x next-fiscal-year adjusted EPS of $11.585—roughly one turn above the five-year average P/E. That is a fair-to-slightly-rich price for a defensive compounder with mid-single-digit-plus growth; the negative PEG is not meaningful here because of one-off GAAP distortions.

The market is paying ~23x forward earnings, meaning the stock already reflects the re-acceleration story: Tremfya up 71%, Darzalex above $4B per quarter, and guidance raised for 2026. To justify further upside, JNJ must prove Stelara's 56% biosimilar-driven revenue decline can continue to be offset and deliver a credible longer-term growth plan at the December 8, 2026 business review. If growth disappoints, multiple compression back toward 20-21x forward earnings would put fair value around $235-245; if execution beats, the bias is toward the ~$280 consensus.

As of 2026-08-27, RSI-14 is 53.4, which is neutral—neither overbought nor oversold. Price is +0.85% above the 20-day, +3.23% above the 50-day, and +13.8% above the 200-day, so the primary trend is up, but the stock is extended versus its 200-day and pulled back ~1.6% on the day after approaching $276. For an individual investor, this suggests holding rather than chasing; a pullback toward the 50-day, roughly $257, would be a more attractive entry.

• Large-cap healthcare is receiving defensive rotation as technology-sector volatility and macro uncertainty push capital toward low-beta (0.23) cash-flow compounders.
• Interest-rate expectations influence the multiple; JNJ is effectively a bond-proxy/Dividend King, so lower rates support the stock while higher rates pressure it.
• Drug-pricing regulation, IRA negotiation, and tariff costs (roughly $500M headwind) create a manageable but real pricing and margin overhang.
• Biosimilar competition, highlighted by Stelara down 56%, is a patent-cliff dynamic forcing pharma to depend on new launches and pipeline strength.
• Talc litigation remains an episodic headline overhang, but so far it has not disrupted operations or damaged the balance sheet.

• Q3 2026 earnings in mid-October: key test of whether Tremfya, Darzalex, and MedTech can keep offsetting Stelara erosion.
• Enterprise Business Review on December 8, 2026: expected to outline a path toward double-digit revenue growth into the end of the decade.
• Pipeline and portfolio execution: China approval of an oral psoriasis therapy, robotic surgery and cardiovascular expansion, and tuck-in M&A such as Expanding Innovations.
• Potential further guidance raise if Innovative Medicine momentum continues through the second half of 2026.

• Stelara biosimilar erosion is severe at -56% YoY and could accelerate faster than new products can fill the gap.
• Valuation is rich relative to its own history, and consensus upside is limited; a growth miss could trigger multiple compression.
• Talc litigation, drug-pricing pressure, tariffs, and regulatory actions are recurring overhangs.
• MedTech growth is tepid at 3.6% operational, leaving the growth burden largely on Innovative Medicine.

JNJ is a high-quality defensive compounder with an improving product cycle, a fortress balance sheet, and a 64-year dividend growth streak, but at ~23x forward earnings the valuation already reflects those positives. It is a reasonable stock to own and collect the dividend for the long term, not an obvious bargain at this price; meaningful upside depends on execution and the December strategic update rather than multiple expansion.

Calculated by applying a 22.5x forward P/E multiple to FY2026 consensus adjusted EPS of $11.585. That multiple is a modest premium to the 20.4x five-year average, justified by ~7% EPS growth, strong margins, and defensive cash flows, but capped by Stelara erosion, modest MedTech growth, and litigation/tariff overhangs—yielding a fair value of $260.66, slightly below the current price of $265.77.